-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NBTXR-3 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NBTXR-3 in Non-Small Cell Lung Cancer Drug Details: NBTXR-3 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CCAR-039 in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CCAR-039 in Diffuse Large B-Cell Lymphoma Drug Details: CCAR-039 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CCAR-039 in Primary Mediastinal B-Cell Lymphoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CCAR-039 in Primary Mediastinal B-Cell Lymphoma Drug Details: CCAR-039 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NBTXR-3 in Oral Cavity (Mouth) Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NBTXR-3 in Oral Cavity (Mouth) Cancer Drug Details: NBTXR-3 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NBTXR-3 in Metastatic Liver Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NBTXR-3 in Metastatic Liver Cancer Drug Details: NBTXR-3 is under development for the treatment of head...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NBTXR-3 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NBTXR-3 in Pancreatic Ductal Adenocarcinoma Drug Details: NBTXR-3 is under development for the treatment of head...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NBTXR-3 in Laryngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NBTXR-3 in Laryngeal Cancer Drug Details: NBTXR-3 is under development for the treatment of head and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NBTXR-3 in Hypopharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NBTXR-3 in Hypopharyngeal Cancer Drug Details: NBTXR-3 is under development for the treatment of head and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nirogacestat Hydrobromide in Soft Tissue Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nirogacestat Hydrobromide in Soft Tissue Sarcoma Drug Details: Nirogacestat hydrobromide (PF-03084014-04) is under development for...
-
Product Insights
![]()
3T Vastgoed/ AM BV/ Boelens de Gruyter/ Bouwfonds / G&S Vastgoed/ Greystar RE/ Janssen de Jong Caribbean/ Lingotto City/ Ramphastos Invest/ Synchroon/ Utrecht City – MerwedeKanaalzone Residential District – Utrecht
Equip yourself with the essential tools needed to make informed and profitable decisions with our 3T Vastgoed/ AM BV/ Boelens de Gruyter/ Bouwfonds / G&S Vastgoed/ Greystar RE/ Janssen de Jong Caribbean/ Lingotto City/ Ramphastos Invest/ Synchroon/ Utrecht City - MerwedeKanaalzone Residential District - Utrecht report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may...
-
Sector Analysis
![]()
Venous Thromboembolism Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032
Venous Thromboembolism Market Report Overview Venous Thromboembolism market size across the 7MM was valued at $3.57 billion in 2022 and is expected to achieve a CAGR of more than 2% during 2022-2032. The US is the most significant contributor to that revenue due to the large size of the VTE patient population in the US as well as the higher overall price of drugs as compared to the 5EU and Japan. Venous Thromboembolism Market Outlook, 2022-2032 ($ Billion) To gain...
-
Product Insights
![]()
Transmucosal Drug Delivery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Transmucosal Drug Delivery Pipeline Market Report Overview A Transmucosal drug delivery device is intended for the localized delivery of medications through a mucous membrane. The transmucosal drug delivery pipeline market research report provides comprehensive information about the transmucosal drug delivery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key Segment ·      Nasal ·      Vaginal ·      Buccal Delivery ·      Rectal Key Territories ·      The US...
-
Company Profile
![]()
Paige.AI Inc – Company Profile
Paige.AI Inc (Paige.AI) is a provider of digital diagnostics solutions. The company utilizes next generation computational technology, machine learning, artificial intelligence to help pathologists by providing information from digital slides and extracting new diagnostic information from pathology slides and samples to support in treatment pathways for patients with cancer. It provides research products such as Paige Prostate Research, a prostate cancer solution that detects, grades and quantifies areas for cancer, and Paige Breast Research, a breast cancer solution that identifies...
Add to Basket -
Sector Analysis
![]()
Psoriatic Arthritis (PsA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Psoriatic Arthritis (PsA) Marketed and Pipeline Drugs Report Overview PsA is a chronic immune-mediated arthritis that typically affects the large joints, including those of the lower extremities, the distal joints of the fingers and toes, the back, and the sacroiliac joints of the pelvis. Clinical diagnosis and assessment of PsA involve a combination of patient history, physical examination, laboratory tests, and imaging studies. The goal of diagnosis and assessment is to identify the presence and extent of joint involvement, assess...
-
Product Insights
![]()
Diabetes Assays Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Diabetes Assays Pipeline Market Report Overview Diabetes assays comprises of C-Peptide Assay, Glycated Hemoglobin (HbA1c) Lab Assay, Glycated Hemoglobin (HbA1c) Point of care (POC) Assay, Insulin Assay, and Fasting Glucose Assay. C-Peptide is a single chain polypeptide secreted by the pancreatic ß-cells in equimolar amounts to Insulin. Insulin is a metabolism regulating hormone secreted by ß-cells of the islets of Langerhans of the pancreas. Diabetes assays pipeline market research report provides comprehensive information about the diabetes assays pipeline products with...
-
Company Profile
![]()
UroGen Pharma Ltd – Company Profile
UroGen Pharma Ltd (UroGen Pharma), formerly TheraCoat Ltd, is a biopharmaceutical company that develops novel medicines to treat cancer indications and urologic diseases. The company products include Jelmyto is a drug formulation of mitomycin used to treat low-grade upper tract urothelial cancer. Its pipeline products include UGN-102 is a mitomycin gel is used to treat low-grade intermediate risk non-muscle invasive bladder cancer, UGN-201 and UGN-302 targets high-grade non-muscle invasive bladder cancer and Botox or RTgel for the treatment of overactive...
Add to Basket -
Company Profile
![]()
Eisai Inc – Company Profile
Eisai Inc (Eisai America), a subsidiary of Eisai Co Ltd, is a healthcare company that discovers, develops, and markets pharmaceutical products. The company's major products include Aricept for Alzheimer’s treatment, Aciphex for acid reflux, Akynzeo for nausea and vomiting during the course of cancer chemotherapy, Aloxi anti-nausea medication injection, Banzel for adjunctive treatment, Dayvigo for the insomnia, and Panretin for the treatment of skin lesions in AIDS-related Kaposi's sarcoma. The company’s research and development activities focus on therapeutic areas such...
Add to Basket -
Company Profile
![]()
Astex Pharmaceuticals Inc – Company Profile
Astex Pharmaceuticals Inc (Astex Pharmaceuticals), a subsidiary of Otsuka Holdings Co Ltd, is a drug discovery and development company with a focus on cancer and central nervous system (CNS) diseases. The company’s proprietary fragment-based drug discovery platform, Pyramid delivers high-quality and customized drug leads across a variety of therapeutic targets and disease areas. Its pipeline product and programs include DNMT inhibitor, Oral DNMT inhibitor, dual IAP antagonist, oral murine double minute 2 (MDM2) antagonist and extracellular signal-related protein kinases inhibitor....
Add to Basket -
Company Profile
![]()
Idorsia Pharmaceutical Ltd – Company Profile
Idorsia Pharmaceutical Ltd (Idorsia) is a biopharmaceutical company that discovers, develops, and commercializes small molecules to treat the central nervous system and cardiovascular and immunological disorders. It is investigating daridorexant against insomnia, aprocitentan for the treatment of resistant hypertension, clazosentan to treat cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage, and L-lucerastat compound targeting fabry disease. The company is also evaluating drugs against suspected acute myocardial infarction, systemic lupus erythematosus, Binge eating disorder and rare lysosomal storage disorders. It works in...
Add to Basket -
Company Profile
![]()
Addex Therapeutics Ltd – Company Profile
Addex Therapeutics Ltd (Addex) is a clinical-stage pharmaceutical company that discovers, develops and commercializes small-molecule pharmaceutical products, including allosteric modulators for neurological disorders. The company develops its proprietary clinical and preclinical-stage drug candidates using its allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) intended to treat Parkinson's disease levodopa-induced dyskinesia. It also carries out clinical and preclinical programs for various indications such as dystonia, epilepsy, post-traumatic stress disorder, Schizophrenia, Other Psychosis, addiction,...
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.